OXFORD EMERGENT TUBERCULOSIS CONSORTIUM LTD.
Oxford Emergent Tuberculosis Consortium Ltd. develops advanced vaccine for the prevention of tuberculosis.
OXFORD EMERGENT TUBERCULOSIS CONSORTIUM LTD.
Industry:
Biotechnology Health Care Pharmaceutical
Address:
Southampton, Southampton, United Kingdom
Country:
United Kingdom
Status:
Active
Similar Organizations
FK Laboratoriz
FK Laboratoriz is develops and markets drug for the treatment and prevention of thrombosis.
More informations about "Oxford Emergent Tuberculosis Consortium Ltd."
Emergent BioSolutions and the University of Oxford Form Joint …
Tuberculosis Vaccine Initiative (SATVI) in Worcester, South Africa. The Consortium has secured GBP 8 million (approximately $16 million) from The Wellcome Trust and the Aeras Global TB …See details»
TB vaccine enters new clinical trials | University of Oxford
Apr 23, 2009 The Oxford-Emergent Tuberculosis Consortium Ltd, a joint venture between the University of Oxford and Emergent BioSolutions Inc, is taking the vaccine forward. ... The …See details»
Oxford-Emergent Tuberculosis Consortium Signs Commercial …
OXFORD, England, ROCKVILLE, Md. & BERLIN–(BUSINESS WIRE)–May. 5, 2009– The Oxford-Emergent Tuberculosis Consortium Ltd., a joint venture between the University of Oxford and …See details»
New Tuberculosis Vaccine Enters Phase IIb Proof-of-Concept Trial …
Aug 11, 2011 The Oxford-Emergent Tuberculosis Consortium Ltd ("OETC")is a joint venture between the University of Oxford and Emergent BioSolutions. OETC was formed with the aim …See details»
TB Vaccine Enters New Clinical Trials | ScienceDaily
May 1, 2009 The Oxford-Emergent Tuberculosis Consortium Ltd is a joint venture between the University of Oxford and Emergent Product Development UK Ltd. The Consortium was formed …See details»
Oxford Emergent Tuberculosis Consortium Ltd. - Crunchbase
Oxford Emergent Tuberculosis Consortium Ltd. is located in Southampton, Southampton, United Kingdom. Who are Oxford Emergent Tuberculosis Consortium Ltd. 's competitors? …See details»
Oxford University Innovation licenses tuberculosis vaccine
OXFORD, UK and ROCKVILLE, MD July 23, 2008—The University of Oxford and Emergent BioSolutions Inc. (NYSE:EBS) announced today that they have formed a joint venture, The …See details»
OXFORD-EMERGENT TUBERCULOSIS CONSORTIUM LIMITED
More for OXFORD-EMERGENT TUBERCULOSIS CONSORTIUM LIMITED (06631227) Registered office address Latimer House, 5 Cumberland Place, Southampton, Hampshire, …See details»
Policy-driven ecosystems for new vaccine development - PMC
Sep 5, 2014 The Oxford-Emergent Tuberculosis Consortium Ltd (“OETC”) had been developing the world’s most clinically advanced new TB vaccine candidate MVA85A/AERAS-485 …See details»
Oxford-Emergent Tuberculosis Consortium - VentureRadar
OETC Ltd is a joint venture between the University of Oxford and Emergent BioSolutions Inc, formed to develop the world’s most clinically advanced new tuberculosis vaccine – MVA85A. …See details»
Oxford-Emergent Tuberculosis Consortium Signs ... - Emergent …
He Oxford-Emergent Tuberculosis Consortium Ltd., a joint venture between the University of Oxford and Emergent BioSolutions Inc. (NYSE:EBS), announced today the signing of a …See details»
Emergent BioSolutions, University of Oxford form JV to develop ...
The University of Oxford and Emergent BioSolutions Inc. announced that they have formed a joint venture, The Oxford-Emergent Tuberculosis Consortium Ltd. (the "Consortium"), to further …See details»
The Oxford-Emergent Tuberculosis Consortium Ltd.: Drug …
Jul 5, 2023 Explore The Oxford-Emergent Tuberculosis Consortium Ltd. with its drug pipeline, therapeutic area, technology platform, 1 clinical trial, Drug:MVA-85A. Data. Feature. Plans. …See details»
Oxford Emergent Tuberculosis Consortium Ltd. - Crunchbase
Oxford Emergent Tuberculosis Consortium Ltd. develops advanced vaccine for the prevention of tuberculosis.See details»
New TB Vaccine Candidate Enters Phase IIb Proof-of-Concept Trial …
Apr 23, 2009 The Oxford-Emergent Tuberculosis Consortium Ltd "OETC" is a joint venture between the University of Oxford and Emergent Product Development UK Ltd. OETC was …See details»
Oxford and Emergent Biosolutions form TB vaccine consortium
Jul 22, 2008 Consortium formedThe University of Oxford and Emergent BioSolutions Inc. have announced a joint venture, The Oxford–Emergent Tuberculosis Consortium Ltd, to develop …See details»
Oxford-Emergent venture gains $16M for TB vaccine trial
Jul 23, 2008 The University of Oxford and Emergent BioSolutions have formed a joint venture--The Oxford-Emergent Tuberculosis Consortium--to further develop MVA85A, an experimental …See details»
Oxford-Emergent Tuberculosis Consortium Vaccinates Last Infant …
Emergent BioSolutions Inc. (NYSE:EBS) announced today that its joint venture with the University of Oxford (Oxford), the Oxford-Emergent Tuberculosis Consortium (OETC), has vaccinated …See details»
Emergent BioSolutions and Oxford University form TB Vaccine jv
Jul 24, 2008 The University of Oxford, through its technology transfer office, Isis Innovation Ltd, has exclusively licensed the MVA85A tuberculosis vaccine candidate and related technology …See details»
TB vaccine MVA85A trial: first volunteers enrolled in Senegal
The Oxford-Emergent Tuberculosis Consortium Ltd (“OETC”) is a joint venture between the University of Oxford and Emergent BioSolutions company. OETC was formed with the aim of …See details»